AI assistant
Immuron Ltd — Regulatory Filings 2016
Jan 13, 2016
35121_rns_2016-01-13_7cabebff-e789-44fa-a135-b8ac8f5bedd6.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [213 x 60] intentionally omitted <==
Analyst Reports on Immuron IMM-529 C. difficile Program
14 January 2015, Melbourne, Australia : Immuron Limited (ASX:IMC) wishes to advise investors and shareholders that RedChip Companies Inc. (RedChip), a company Immuron engaged for the provision of certain US investor relations services, has released a research report specifically highlighting the recent IMM-529 results from the Company’s C. difficile recurrence studies.
Two other US-based companies with C. difficile Phase II clinical trials have market capitalisations more than 5 times that of Immuron’s market capitalisation.
This C. difficle program adds further value to Immuron’s existing product portfolio of two over-the-counter consumer products (Travelan and Protectyn), and its NASH and ASH Phase IIb Clinical Trials.
A copy of the RedChip’s research update will be made available on the Immuron Company website at: http://immuron.com/investor-centre/analyst-reports/.
| Company Contact: | Immuron US Investor Relations: | |
|---|---|---|
| Thomas Liquard | Jon Cunningham | |
| Chief Executive Officer | RedChip Companies, Inc. | |
| AUS Ph: +61 (0)3 9824 5254 | US Ph: +1 (407) 644 4256, (ext. 107) | |
| [email protected] | [email protected] |
About Immuron:
Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.
For more information visit: http://www.immuron.com/
Forward-Looking Statements:
Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.
Suite 1, 1233 High Street www.immuron.com Armadale, Victoria AUSTRALIA 3143 ABN: 80 063 114 045
Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735